Osteoarthritis (OA) of the knee joint is characterized pathologically by loss of articular cartilage and clinically by pain and disability. Its prevalence will increase rapidly over the next 20 years (
1). The occurrence of OA is related to age, obesity, trauma, genetics and various pathophysiological events within the joints (
2). It is also associated with major cellular and molecular alterations in articular tissue. Inflammatory factors such as cytokines, nitric oxide, prostaglandin E2 (inflammatory pain mediators), neuropeptides and proteolytic enzymes are produced by the inflamed synovium (
3). Chondrial changes include cartilage fragmentation (fibrillation), presence of tear, loss of type II collagen, chondrocyte apoptosis and loss of proteoglycans. As one grows older, the ability of chondrocytes to maintain and restore of articular cartilage decreases (
4). Articular cartilage is composed of chondrocytes and extracellular matrix (ECM) and the ECM is composed mainly of collagen fibers type II (
5). The balance of collagen and Proteoglycan (PG) is reject disrupted in OA, and proteoglycans are disrupted in OA and trauma. Early stages of OA, are characterized by a decrease in proteoglycans and collagen, change in cartilage properties, activation of some degenerative enzymes and reduction of aggrecan size (
6). The breakdown of type II collagen appears in later stages of OA and follows the degradation of PG (
7). It is clear that both mechanical and biological factors are involved in degeneration of cartilage, decreased synthesis of ECM and formation of chondrocyte clusters (
8). In other words, the number of cells remains unchanged yet distribution of their arrangement occurs, and highly cellular clone formation related to the disability of proliferated cells to migrate in damaged areas. Chondrocytes attach to ECM proteins, via integrin receptors and this adhesion is implicated in OA and leads to cartilage fibrillation (
2). Growth factors such as IGF-1 or TGF-β contribute to chondrocyte adhesion to fibronectin (
9). It has been established by animal models of OA, that the intra-articular injection of Monosodium Iodoacetate (MIA) acts as an inhibitor of glycolysis and promotes loss of articular cartilage similar to OA and produces necrosis with degeneration of chondrocyte in tibial plateaus and femoral condyles (
10). Despite the high prevalence of OA, an effective treatment is currently lacking. Difficulties of studying OA in humans have led to highly dynamic animal models (
11). There are different pharmacologic and non-pharmacologic methods for treatment of OA; however the application of cell–based therapies has been used for a number of decades (
12). Bone marrow is the main source for isolation of Mesenchymal Stem Cells (MSCs), and these cells have the potential to differentiate to a variety of cells of different tissues (
13). The application of MSCs for OA repair requires different techniques, although the local injection of MSCs may be the simplest procedure (
14).
There are two administration methods of stem cells: direct or local and intravascular administration. Numerous researchers have discussed the use of MSCs to repair a variety of tissues (
15). The structural damages of articular cartilage have been demonstrated in a variety of ways such as clefts. Proteoglycan loss and collagen breakdown have been observed by microscopic slides (
16). It is clear that MSCs are suited for cartilage repair. These cells facilitate regeneration, by secreting nutrient and bioactive factors (
17).